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Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare type of anti-
neutrophil cytoplasm antibody-associated vasculitis (AAV) with unique features, 
such as involvement of eosinophils in the pathogenesis, which requires different 
therapies from those used for other AAV. Conventional treatment includes gluco-
corticoids (GC) and immunosuppressants. GC are the cornerstone of the initial 
treatment of EGPA, but relapses are frequent. Cyclophosphamide is typically used 
in combination with GC for patients with life- and/or organ-threatening disease 
manifestations. Azathioprine and methotrexate are recommended to maintain 
remission after induction with cyclophosphamide or as a GC-sparing agent. 
Nowadays, a better comprehension of the physiopathology of EGPA has opened 
new therapeutic targets, such as interleukin-5, which has a key role in the refrac-
tory disease, relapses, and GC dependence, especially for asthma manifestations. 
Mepolizumab is the first anti-IL5 antibody approved to treat EGPA. Another 
anti-IL5 monoclonal antibody, reslizumab, and an anti-IL5 receptor monoclonal 
antibody, benralizumab, are now being investigated for EGPA.
Keywords: eosinophilic granulomatosis with polyangiitis, Churg-Strauss syndrome, 
vasculitis, eosinophilia, anti-IL5 therapy, glucocorticoids, cyclophosphamide, 
mepolizumab
1. Introduction
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss 
syndrome, is a rare necrotizing vasculitis, with an annual incidence and prevalence 
of 0.9–2.4 per million [1–4] and 10.7–17.8 per million [5–8], respectively, depending 
on geographic regions and applied criteria. The disease is now recognized as one 
form of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) 
characterized by eosinophil-rich granulomatous inflammation and small to medium 
size vessel vasculitis associated with asthma and eosinophilia [9].
ANCA occur only in about 30–70% of patients with newly diagnosed untreated 
EGPA, and organ involvement can be different depending on the presence or not of 
ANCA [10], probably being different subgroups with specific characteristics. In this 
way, Matsumoto et al. [11] reported that AAV patients could be divided into three 
subgroups according to peripheral immune cell numbers: antibody production 
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related, cytotoxic activity related, and neutrocytosis/lymphocytopenia. These 
subgroups could have different prognosis and treatment.
EGPA has been excluded from most of randomized controlled trials for AAV 
because of its rarity and unique features, such as involvement of eosinophils in the 
pathogenesis. Reliable evidence of treatment for EGPA is limited, and there are no 
strong recommendations for treatment of EGPA at the moment [12].
Treatment has been based on the use of glucocorticoids (GC) and immunosup-
pressants. Cyclophosphamide is typically used in combination with GC for patients 
with poor prognostic factors (assessed by the Five Factor Score). Azathioprine 
and methotrexate are recommended to maintain remission after induction with 
cyclophosphamide or as a GC-sparing agent. All these medications have many and 
deleterious adverse effects.
Fortunately, a better comprehension of the physiopathology of EGPA has opened 
new therapeutic targets, such as interleukin-5, which has a key role in the disease.
2. Assessing vasculitis severity
The French Vasculitis Study Group conducted two randomized controlled clini-
cal trials to develop a score to assess the severity of vasculitis disease: the Five Factor 
Score (FFS) [13].
The FFS is a prognostic tool used to quantify the extent of the disease and guide 
therapy. It consists of five items. Age >65 years old, cardiac insufficiency, severe 
gastrointestinal involvement, and renal insufficiency [stabilized peak creatinine 
1.7 mg/dL {150 μmol/L}] are associated with poor prognoses, each scores +1 point, 
while the fifth factor (ear, nose, and throat [ENT] manifestations) is associated 
with better outcome and its absence is scored +1 point.
3. Conventional therapy for EGPA
3.1 Systemic glucocorticoids
Glucocorticoids are the cornerstone of the initial treatment of EGPA. They act 
quickly against vasculitis and normalize the value of peripheral eosinophils within 
few days of treatment.
A multicenter retrospective study, done by Cottin et al. [14] in 2016, showed that 
treatment with systemic GC was associated to a decrease in peripheral eosinophilia 
(with a mean cell count <1.0 × 109 L−1 over the long-term).
The initial management of EGPA includes high doses of GC, usually 1 mg/kg/day of 
prednisone or its equivalent. Methylprednisolone pulses (7.5–15 mg/kg intravenously, 
repeated at 24 h intervals, for 3 days) can be used in the presence of life-threatening 
symptoms. When clinical response is obtained and inflammation reactants return to 
normal values, usually within 3–4 weeks, GC can be tapered slowly to the minimal 
effective dose or, when possible, until withdrawal. However, most patients need to 
maintain GC to prevent relapses of systemic manifestations and control asthma. The 
optimal minimal dose should be 7.5 mg/day to limit GC-induced side effects [15, 16].
In the French Vasculitis Study Group cohort [17], which included 383 EGPA 
patients, approximately 85% required long-term prednisone (mean dose 
12.9 ± 12.5 mg/day) to control asthma, rhinitis, and/or arthralgias.
GC as monotherapy may be suitable for most EGPA patients. In a study, which 
included 72 EGPA patients without poor prognosis factors, 93% achieved remission 
with systemic GC therapy alone [18]. However, additional immunosuppression can 
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be considered for patients with life- and/or organ-threatening disease, when the 
prednisone dose cannot be tapered to 7.5 mg/day after 3–4 months of therapy or for 
patients with recurrent disease [16, 19].
Samson et al. [20] assessed the outcomes of 118 EGPA patients (with or without 
FFS) enrolled in two prospective, randomized, open-label clinical trials from 1994 
to 2005. Forty-four patients with poor prognosis (FFS ≥ 1) were assigned to receive 
6 or 12 cyclophosphamide (CPh) pulses plus GC, and 74 without poor prognosis fac-
tors (FFS = 0) received GC alone (with immunosuppressant [IS] adjunction when 
GC failed). Follow-up was done from 2005 to 2011. Twenty-nine percent achieved 
long-term remission, while 41% had ≥1 relapse at 26 months after treatment onset. 
More than half of the relapses occurred when GC tapering reached <10 mg/day, 




Cyclophosphamide is typically used in combination with GC for patients with 
life- and/or organ-threatening disease manifestations (i.e., heart, gastrointestinal 
involvement, central nervous system, severe peripheral neuropathy, severe ocular 
disease, alveolar hemorrhage, and/or glomerulonephritis) [14].
In a retrospective study of 595 patients with severe necrotizing vasculitides 
(including EGPA), treatment had no significant impact on early death, except for 
patients with FFS ≥ 2 for whom GC monotherapy showed association (p < 0.05). 
The principal cause of early death was uncontrolled vasculitis (58%), followed by 
infection (26%) [21]. A study of 278 patients with polyarteritis nodosa, microscopic 
polyangiitis, and EGPA showed that survival was significantly higher in patients 
with FFS > 2 treated with GC and CPh rather than GC alone [22].
Cyclophosphamide can be administered as continuous oral therapy or intrave-
nous (IV) pulses. The doses should be adjusted according to age and renal function. 
Cyclophosphamide pulses are usually preferred to oral administration because of 
the lower cumulative dosage. The frequency of relapses, however, can be higher with 
pulses, and it has been shown that oral CPh can be effective when pulses have failed 
[15]. Sodium 2-mercaptoethanesulfonate is recommended to reduce bladder toxicity.
Regarding the duration of CPh therapy, Cohen et al. [23] conducted a prospec-
tive, multicenter trial to compare first-line treatment with systemic GC and 6 or 
12 pulses of adjunctive CPh for the treatment of severe EGPA. Forty-eight patients 
were included, 42 (87.5%) achieved complete remission, 21 (91.3%) in the 6-pulse 
regimen, and 21 (84%) in the 12-pulse regimen. Severe side effects were similar in 
both groups. However, a too-short duration of CPh administration was associated 
with more relapses, so the authors concluded that a 12-pulse regimen was better to 
control severe EGPA than a 6-pulse regimen. Other less toxic IS, as azathioprine 
(AZA) or methotrexate (MTX), were not tested for maintenance so further data is 
needed to clarify the optimal duration of therapy.
3.2.2 Azathioprine and methotrexate
AZA and MTX are recommended to maintain remission after induction 
with CPh or as a GC-sparing agent in patients requiring long-term therapy with 
prednisone at doses >10 mg/day. Maintenance therapy with an IS usually begins 
2–3 weeks after the last CPh pulse, or a few days after oral CPh, and continues for 
12–18 months [16].
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Pagnoux et al. [24] conducted a prospective, open-label, multicenter trial to 
evaluate the safety and efficacy of AZA and MTX in ANCA-associated vasculitis. 
One hundred twenty-six patients in remission with IV CPh and GC were randomly 
assigned to receive AZA (at a dose of 2.0 mg/kg/day) or MTX (at a dose of 0.3 mg/
kg/week, progressively increased to 25 mg per week) as maintenance therapy for 
12 months. Adverse events occurred in 29 AZA recipients and 35 MTX recipients. 
There was one death in the MTX group. Twenty-three patients who received AZA 
and twenty-one patients who received MTX had a relapse. The results suggested 
that none of the drugs were more effective at maintaining remission, but severe 
adverse events were more frequent in the MTX group.
4. New therapeutic strategies
4.1 Role of IL-5 in EGPA
EGPA is characterized by elevated peripheral eosinophilia with different degrees 
of activation. Eosinophilia is secondary to more synthesis, enhanced extravasa-
tion, and its prolonged survival in target tissues. Histological features of EGPA are 
small-vessel angiitis and extravascular necrotizing granulomas, usually containing 
eosinophilic infiltrate [25, 26].
An initial Th2-mediated immune response provokes the migration of eosino-
phils to tissues. IL-5, produced by TH-2 lymphocytes, plays an active role in 
chemotaxis, activation, degranulation, and survival of eosinophils [26]. IL-5 is 
not the only mediator of eosinophilic tissue infiltration; IL-4 and IL-13 are two 
other cytokines of Th2-mediated immune response that play an important role 
in tissue infiltration and degranulation of eosinophils [27, 28]. Epithelial and 
endothelial cells, when activated by Th2 cytokines, secrete eosinophil-specific 
chemokines like eotaxin 3 (CCL26), CCL17, and CCL22 that facilitate recruitment 
of eosinophils and effector Th2 cells in target organs, amplifying the immune 
response [29, 30].
A better comprehension of the physiopathology of EGPA highlights the role of 
eosinophils and IL-5. It has been observed that serum level of IL-5 correlates with 
disease activity and that it decreases with the initiation of immunosuppressive 
therapy [30–32].
4.2 Anti-IL-5 antibodies in EGPA
Interleukin-5 is well known as a key mediator in eosinophil activation. Thus, the 
efficacy of mepolizumab, a humanized monoclonal antibody against interleukin-5, 
was evaluated in EGPA patients.
Kahn et al. [33] published the first case of refractory EGPA treated with 
mepolizumab. The patient had many relapses despite treatment with GC, MTX, 
interferon alpha, CPh, IV immunoglobulin, AZA, and etoposide. Mepolizumab 
750 mg IV monthly was started. After the first dose, asthma significantly improved, 
the eosinophil count decreased (reaching normal values), and the chest computed 
tomography (CT) showed complete regression of parenchymal findings. After 
6 months of treatment, asthma symptoms disappeared, and chest CT did not show 
infiltrates, so an attempt to increase the intervals between mepolizumab infu-
sions to 2 months was done which resulted in relapse with reappearance of asthma 
symptoms, interstitial lung infiltrates, and increase of peripheral eosinophilia. All 
parameters normalized with transient increase of prednisone and reintroduction of 
mepolizumab monthly infusions.
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A single-center, phase 2, uncontrolled, investigator-initiated trial [34] included 
10 consecutive patients with refractory or relapsing EGPA. Relapse was defined by 
a Birmingham Vasculitis Activity Score (BVAS) >3 despite treatment with IS plus 
GC at a dosage of 12.5 mg/day or higher. After stopping previous IS, the patients 
received nine infusions of mepolizumab, 750 mg monthly. Then it was switched to 
MTX maintenance therapy and a tapered dosage of GC as tolerated. Eight patients 
reached remission (BVAS = 0 and GC dosage <7.5 mg/day) after two or three mepo-
lizumab infusions. One patient had a partial response (BVAS = 0 but did not achieve 
a GC dosage <7.5 mg/day), and another patient reached remission but was excluded 
owing to nonadherence. During mepolizumab treatment, no relapse occurred, the 
daily GC dose was reduced in all patients, and eosinophil count decreased after the 
first infusion. After switching mepolizumab to MTX, seven relapses occurred, over 
a median follow-up of 10 months. The same authors, in a later work [35], followed 
up these nine patients during a median of 22 months. Only three of them were still 
in remission at the end of the study. So, a high relapse rate after stopping mepoli-
zumab was observed, which suggests that patients with EGPA could need a continu-
ous treatment with mepolizumab.
An open-label pilot study [36] treated seven patients with four monthly doses of 
mepolizumab 750 mg IV to assess its steroid-sparing effect in GC-dependent EGPA 
patients. Mepolizumab allowed for safe GC reduction in all patients. The GC mean 
dose at baseline was 12.9 mg/day and after 12 weeks of therapy was 4.6 mg/day 
(64% reduction). On cessation of mepolizumab, EGPA manifestations recurred, 
needing steroid bursts. Mepolizumab was well tolerated, and the most frequent 
adverse events were headache, pruritus, and loose stools.
In 2017, a multicenter, double-blind, parallel-group, phase three trial was 
published [37]. It included 136 patients with relapsing or refractory EGPA, who 
had received treatment for at least 4 weeks and were taking a stable prednisolone 
or prednisone dose. They were randomized to receive 300 mg of mepolizumab 
(n = 68) or placebo (n = 68), administered subcutaneously (SC) every 4 weeks, 
plus standard care, for 52 weeks. Mepolizumab treatment led to significantly more 
accrued weeks of remission (defined as BVAS = 0 and prednisolone or predni-
sone ≤4 mg/day) than placebo (28 vs. 3% of the participants had ≥24 weeks of 
accrued remission) and a higher percentage of participants in remission at both 
weeks 36 and 48 (32 vs. 3%). Remission did not occur in 47% of the participants 
in the mepolizumab group vs. 81% of those in the placebo group. A total of 44% 
of the participants in the mepolizumab group, as compared with 7% of those in 
the placebo group, had an average daily dose of prednisolone or prednisone of 
≤4 mg/day during weeks 48 through 52. Eighteen percent of the patients receiving 
mepolizumab were able to discontinue prednisolone or prednisone completely, as 
compared with 3% receiving placebo. Also, time to first relapse was longer, and 
annualized relapse rate was lower in the participants in the mepolizumab group. 
The most commonly adverse events with mepolizumab were headache, nasophar-
yngitis, arthralgia, sinusitis, and upper respiratory tract infection. A post hoc 
analysis [38] of the results according to peripheral eosinophilia (<150 cells/μl), GC 
dosage (>20 mg/day), and weight (>85 kg) was done. It showed that those patients 
treated with mepolizumab, with peripheral eosinophilia <150 cell/μl and weight 
>85 kg, had greater clinical benefit (BVAS = 0 and GC dosage ≤4 mg/day) than 
placebo. Although no significant differences were found in patients treated with GC 
dosage >20 mg/day, results favored mepolizumab treatment, but it must be consid-
ered that the study include few cases (n = 21).
Recently, Shiroshita et al. [39] published a case report of a 61-year-old man 
with refractory EGPA despite treatment with GC, CPh, and plasmapheresis who 
developed a diffuse alveolar hemorrhage. Rituximab and methylprednisolone 
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pulses were administered, and remission was obtained. Then mepolizumab 100 mg 
SC monthly was started that kept remission until now. To our knowledge, this is the 
first published paper where the authors used, in an EGPA patient, the same dosage 
and way of administration of mepolizumab used in severe asthma.
The Food and Drug Administration (FDA) approved the use of mepolizumab in 
adult patients with EGPA in the United States (USA), in December 2017, based on 
Wechsler [5] results, being the first biological treatment approved with this indica-
tion in data sheet [40–42]. The dosage of 300 mg, three times the recommended 
dose in severe eosinophilic asthma, is based on observations done in asthma, but no 
specific dose evaluation has been done in EGPA [42].
Another anti-IL5 monoclonal antibody, reslizumab, and an anti-IL5 recep-
tor monoclonal antibody, benralizumab, are now being investigated for EGPA 
(NCT02947945 and NCT03010436, respectively) [43, 44].
5. Conclusions
The pathogenesis and role of ANCA in EGPA are mostly unknown, although it 
has been reported that patients with positive ANCA usually present renal involve-
ment (glomerulonephritis), while those with negative ANCA usually have cardiac 
involvement (heart failure), possibly corresponding to two different subgroups 
with different characteristics still to be determined which will provide information 
and facilitate specific treatments. GC and IS are effective in EGPA, but relapses are 
frequent, and there is no standard therapy based on the results of randomized clini-
cal trials. However, there is new data that shows mepolizumab as a good treatment 
option due to its clinical benefit, and its use in EGPA has recently been approved in 
the United States.
Advances in the knowledge of EGPA pathophysiology together with the appear-
ance of new drugs, such as mepolizumab, seems to be a solution to the unmet needs 
in this disease.
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